ATS 2024 Final Program

Click on the session title to view the speakers

154

MONDAY • MAY 20

P1269 The Utility of Cardiopulmonary Exercise Testing in Diagnosing Dyspnea of Unclear Etiology P1270 The Impact of Age on Adequate Performance and Results in Cardiopulmonary Exercise Testing P1271 Concordance Between Measured and Calculated Maximum Voluntary Ventilation P1272 Assessing Post-COVID-19 Lung Function: A Comprehensive Comparison of HRCT Ventilation Analysis and PFTs in Healthy, Active Individuals P1273 Point-of-Care Ultrasound Contribution for Management of Patients With Acute Dyspnea in the Prehospital Setting: A Systematic Review P1274 Sex-differences in Dyspnea Descriptors in Respiratory Outpatients P1275 Hemoglobin Levels and Their Correlation With Oxygen Uptake and Gas Exchange Parameters During Exercise: Insights From a Retrospective Study P1276 The Effectiveness of Poster Intervention on Oxygen Target Saturation Prescription in a Secondary Care Setting in Glasgow, United Kingdom P1277 Reduced Catecholamine Levels in Patients With Obesity: Exploring the BMI-Catecholamine Link in Unexplained Dyspnea P1278 Pulmonary Symptoms in Post-acute Sequelae of COVID-19 (PASC) Patients With Multiple COVID Infections P1279 Crisis Averted: A Myasthenia Journey P1280 Analysis of Cough Characteristics in Chronic Respiratory Diseases P1281 Obstructive Sleep Apnea and Chronic Cough: Is There Really a Link? P1282 Silent Threats From the Desert: Chronic Cough as the Manifestation of Undiagnosed Coccidioidomycosis P1283 Real World Experience of Gefapixant Prescribing P1284 Breathlessness Relieved by Employing Medical Air Titrated by Hospitalized Patients (BREATH) Randomized Clinical Trial P1285 The Alveolar Gas Monitor Outperforms Pulse Oximetry in Predicting Respiratory Deterioration Among Acutely Dyspneic Individuals

P1258 Striving for Patient-Centered Care: Interim Analysis of Feasibility and Adherence to the European ILD Registry Algorithm for Self Assessment (eurILDreg ASA) P1259 TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis: Annual Update of Preliminary Baseline Data P1260 Study Design and Rationale for the TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis P1261 Analysis of Early Intervention of Nintedanib After Antiinflammatory Treatment in Patients With Non-idiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease: A Single Center Retrospective Study in Japan P1262 Effects of Antifibrotic Therapy in the Real-world Progressive Pulmonary Fibrosis P1263 Tolerance Assessment of Nintedanib by Underlying Disease: A Retrospective Analysis at a Single Center P1264 Crafting a Patient-focused Phase 2b Trial (ASPIRE) to Evaluate Efficacy and Safety of Buloxibutid in Individuals With Idiopathic Pulmonary Fibrosis (IPF) P1265 Does Metformin Influence Clinically Relevant Outcomes in IPF? P1266 Use of Steroid Drugs in Fibrosing Interstitial Lung Diseases - A Modified Delphi Survey B49 RESEARCH STUDIES IN DYSPNEA AND COUGH 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P1268 Safety of Cardiopulmonary Exercise Testing in Patients With Dyspnea of Unclear Etiology San Diego Convention Center Area K (Hall H, Ground Level) CLINICAL THEMATIC POSTER SESSION

ATS 2024 Conference Program • San Diego, CA